Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | CES1 | P23141 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL430932 | 1.00 | LMNA (0.44) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL5173363 | 1.00 | LMNA (0.44) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL10765606 | 0.98 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL8601633 | 0.98 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Water SCHEMBL17513119 | 0.98 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Water SCHEMBL9138593 | 0.98 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Water SCHEMBL17513118 | 0.98 | LMNA (0.43) | LMNAMAPK1SRCCYP2D6CES2 | |
| Benzene SCHEMBL23120173 | 0.98 | LMNA (0.46) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL9036 | 0.98 | LMNA (0.46) | LMNAMAPK1SRCCYP2D6CES2 | |
| SCHEMBL21723253 | 0.98 | LMNA (0.46) | LMNAMAPK1SRCCYP2D6CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-1224667-A | — | — | None | — | — | JP | disclosed |
| EP-4312974-A1 | STABLE OPHTHALMIC COMPOSITION COMPRISING LATANOPROST | actrevo GmbH (DE) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022207454-A1 | STABLE OPHTHALMIC COMPOSITION COMPRISING LATANOPROST | ACTREVO GMBH (DE) | 2022-10-06 | — | — | WO | disclosed |
| US-20170273932-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | ZAFGEN INC (US) | 2017-09-28 | — | — | US | disclosed |
| EP-3182960-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | Zafgen, Inc. (US) | 2017-06-28 | — | — | EP | disclosed |
| WO-2016029206-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | ZAFGEN, INC. (US) | 2016-02-25 | — | — | WO | disclosed |
| EP-0652748-A1 | A METHOD OF INCREASING CREATINE SUPPLY DEPOT | Pharmacia AB (SE) | 1995-05-17 | — | — | EP | disclosed |
| WO-1994002127-A1 | A METHOD OF INCREASING CREATINE SUPPLY DEPOT | HULTMAN ERIC (SE) | 1994-02-03 | — | — | WO | disclosed |
| EP-0525078-A4 | ANTI-LICE TREATMENT COMPOSITIONS | — | 1993-03-31 | — | — | EP | disclosed |
| EP-0525078-A1 | ANTI-LICE TREATMENT COMPOSITIONS. | PROCTER & GAMBLE (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991015953-A1 | ANTI-LICE TREATMENT COMPOSITIONS | THE PROCTER & GAMBLE COMPANY (US) | 1991-10-31 | — | — | WO | disclosed |
| WO-1991015517-A1 | PECTIN-CONTAINING PRODUCT AND METHOD FOR PRODUCING SAME | GRINDSTED PRODUCTS A/S (DANISCO A/S) (DK) | 1991-10-17 | — | — | WO | disclosed |
| EP-0390102-A2 | Process for the preparation of pyridine-2,3-dicarboxylic acids | CELGENE CORPORATION (US) | 1990-10-03 | — | — | EP | disclosed |
| JP-H01224667-A | APPLIANCE FOR DETECTING KETONE BODY | KOKUSAI SHIYAKU KK | 1989-09-07 | — | — | JP | disclosed |
| WO-1988004930-A1 | DIETARY SUPPLEMENT FOR SAFELY ESTABLISHING ALKALINITY RESERVOIR IN ANIMALS | ROHWER GARY LAMONT (US) | 1988-07-14 | — | — | WO | disclosed |
| EP-0218635-A4 | Food composition comprising a base mix and flavourings. | FOOD SCIENCES CORP (US) | 1987-11-23 | — | — | EP | disclosed |
| EP-0218635-A1 | Food composition comprising a base mix and flavourings | FOOD SCIENCES CORPORATION (US) | 1987-04-22 | — | — | EP | disclosed |
| WO-1986005364-A1 | COMPREHENSIVE NUTRITIONAL SYSTEM | FOOD SCIENCES CORPORATION (US) | 1986-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273932-A1 | LYOPHILIZED COMPOSITIONS CONTAINING A METAP-2 INHIBITOR | METAP2, CETP, PMM2 | LMNA 4085/4885MAPK1 3203/4885SRC 3468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.